Serological response following COVID-19 vaccines in patients living with HIV: a dose–response meta-analysis
Abstract To quantify the pooled rate and risk ratio of seroconversion following the uncomplete, complete, or booster dose of COVID-19 vaccines in patients living with HIV. PubMed, Embase and Cochrane library were searched for eligible studies to perform a systematic review and meta-analysis based on...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-06-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-023-37051-x |
| _version_ | 1797795698971770880 |
|---|---|
| author | Qian Zhou Furong Zeng Yu Meng Yihuang Liu Hong Liu Guangtong Deng |
| author_facet | Qian Zhou Furong Zeng Yu Meng Yihuang Liu Hong Liu Guangtong Deng |
| author_sort | Qian Zhou |
| collection | DOAJ |
| description | Abstract To quantify the pooled rate and risk ratio of seroconversion following the uncomplete, complete, or booster dose of COVID-19 vaccines in patients living with HIV. PubMed, Embase and Cochrane library were searched for eligible studies to perform a systematic review and meta-analysis based on PRIMSA guidelines. The pooled rate and risk ratio of seroconversion were assessed using the Freeman-Tukey double arcsine method and Mantel–Haenszel approach, respectively. Random-effects model was preferentially used as the primary approach to pool results across studies. A total of 50 studies involving 7160 patients living with HIV were analyzed. We demonstrated that only 75.0% (56.4% to 89.9%) patients living with HIV achieved a seroconversion after uncomplete vaccination, which improved to 89.3% (84.2% to 93.5%) after complete vaccination, and 98.4% (94.8% to 100%) after booster vaccination. The seroconversion rates were significantly lower compared to controls at all the stages, while the risk ratios for uncomplete, complete, and booster vaccination were 0.87 (0.77 to 0.99), 0.95 (0.92 to 0.98), and 0.97 (0.94 to 0.99), respectively. We concluded that vaccine doses were associated with consistently improved rates and risk ratios of seroconversion in patients living with HIV, highlighting the significance of booster vaccination for patients living with HIV. |
| first_indexed | 2024-03-13T03:22:58Z |
| format | Article |
| id | doaj.art-3048ecb445464498bfc5ad8bcede9e4d |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-03-13T03:22:58Z |
| publishDate | 2023-06-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-3048ecb445464498bfc5ad8bcede9e4d2023-06-25T11:13:54ZengNature PortfolioScientific Reports2045-23222023-06-0113111410.1038/s41598-023-37051-xSerological response following COVID-19 vaccines in patients living with HIV: a dose–response meta-analysisQian Zhou0Furong Zeng1Yu Meng2Yihuang Liu3Hong Liu4Guangtong Deng5Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South UniversityDepartment of Oncology, Xiangya Hospital, Central South UniversityDepartment of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South UniversityDepartment of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South UniversityDepartment of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South UniversityDepartment of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South UniversityAbstract To quantify the pooled rate and risk ratio of seroconversion following the uncomplete, complete, or booster dose of COVID-19 vaccines in patients living with HIV. PubMed, Embase and Cochrane library were searched for eligible studies to perform a systematic review and meta-analysis based on PRIMSA guidelines. The pooled rate and risk ratio of seroconversion were assessed using the Freeman-Tukey double arcsine method and Mantel–Haenszel approach, respectively. Random-effects model was preferentially used as the primary approach to pool results across studies. A total of 50 studies involving 7160 patients living with HIV were analyzed. We demonstrated that only 75.0% (56.4% to 89.9%) patients living with HIV achieved a seroconversion after uncomplete vaccination, which improved to 89.3% (84.2% to 93.5%) after complete vaccination, and 98.4% (94.8% to 100%) after booster vaccination. The seroconversion rates were significantly lower compared to controls at all the stages, while the risk ratios for uncomplete, complete, and booster vaccination were 0.87 (0.77 to 0.99), 0.95 (0.92 to 0.98), and 0.97 (0.94 to 0.99), respectively. We concluded that vaccine doses were associated with consistently improved rates and risk ratios of seroconversion in patients living with HIV, highlighting the significance of booster vaccination for patients living with HIV.https://doi.org/10.1038/s41598-023-37051-x |
| spellingShingle | Qian Zhou Furong Zeng Yu Meng Yihuang Liu Hong Liu Guangtong Deng Serological response following COVID-19 vaccines in patients living with HIV: a dose–response meta-analysis Scientific Reports |
| title | Serological response following COVID-19 vaccines in patients living with HIV: a dose–response meta-analysis |
| title_full | Serological response following COVID-19 vaccines in patients living with HIV: a dose–response meta-analysis |
| title_fullStr | Serological response following COVID-19 vaccines in patients living with HIV: a dose–response meta-analysis |
| title_full_unstemmed | Serological response following COVID-19 vaccines in patients living with HIV: a dose–response meta-analysis |
| title_short | Serological response following COVID-19 vaccines in patients living with HIV: a dose–response meta-analysis |
| title_sort | serological response following covid 19 vaccines in patients living with hiv a dose response meta analysis |
| url | https://doi.org/10.1038/s41598-023-37051-x |
| work_keys_str_mv | AT qianzhou serologicalresponsefollowingcovid19vaccinesinpatientslivingwithhivadoseresponsemetaanalysis AT furongzeng serologicalresponsefollowingcovid19vaccinesinpatientslivingwithhivadoseresponsemetaanalysis AT yumeng serologicalresponsefollowingcovid19vaccinesinpatientslivingwithhivadoseresponsemetaanalysis AT yihuangliu serologicalresponsefollowingcovid19vaccinesinpatientslivingwithhivadoseresponsemetaanalysis AT hongliu serologicalresponsefollowingcovid19vaccinesinpatientslivingwithhivadoseresponsemetaanalysis AT guangtongdeng serologicalresponsefollowingcovid19vaccinesinpatientslivingwithhivadoseresponsemetaanalysis |